WEBProducts. Learn more about our product portfolio and how we're prioritizing vaccines and specialty medicines to get ahead of disease together. Below you can find the full A-Z list of our products available in the United States.
WEBPress releases. October 08 2024 GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV seasons. September 18 2024 GSK announces positive topline data on co …
WEBTogether with GSK Oncology is here to help, offering patients and healthcare professionals a variety of access and reimbursement services for all GSK oncology products—all in one place.
WEBWe’re pushing the frontiers of respiratory science and harnessing the science of the immune system to transform patient outcomes in areas of unmet need, based on decades of innovative research. COPD. Asthma. With over 50 years in respiratory care, GSK is committed to helping patients breathe better by continuously redefining treatment for ...
WEBWe deliver over two million vaccine doses per day to people living in over 160 countries. The vaccines in our portfolio have been helping to protect people from serious disease for well over 100 years, with our Marietta, PA site dedicated to …
WEBGSK has a significant footprint in the US across commercial, R&D, manufacturing, and corporate functions. We employ ~15,000 people across the US and have two corporate hubs. Explore GSK in the US.
WEBGSK has been an established leader in eosinophil research for over 25 years. We are currently supporting more than 60 studies worldwide across 24 countries to progress eosinophil science and strive to treat more patients …
WEBUS FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit.
WEBMay 3, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. This is the first …